The University of Chicago Header Logo

Connection

David T. Rubin to Female

Back to Details
This is a "connection" page, showing publications David T. Rubin has written about Female.
David T. Rubin
Connection Strength
3.080
Female
  1. Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2024 Dec; 69(12):4437-4445.
    View in: PubMed
    Score: 0.046
  2. Dose escalation of biologics in biologic-naive patients with Crohn's disease: Outcomes from the ODESSA-CD study. J Manag Care Spec Pharm. 2024 Nov; 30(11):1276-1287.
    View in: PubMed
    Score: 0.046
  3. Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY. Inflamm Bowel Dis. 2024 Oct 03; 30(10):1776-1787.
    View in: PubMed
    Score: 0.046
  4. An Insight into Patients' Perspectives of Ulcerative Colitis Flares via Analysis of Online Public Forum Posts. Inflamm Bowel Dis. 2024 Oct 03; 30(10):1748-1758.
    View in: PubMed
    Score: 0.046
  5. Impact of a health-system specialty pharmacy on time to upadacitinib initiation. Am J Health Syst Pharm. 2024 Sep 23; 81(19):e594-e600.
    View in: PubMed
    Score: 0.046
  6. Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY. BMC Gastroenterol. 2024 Sep 17; 24(1):314.
    View in: PubMed
    Score: 0.046
  7. The Communicating Needs and Features of IBD Experiences (CONFIDE) Study: US and European Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Ulcerative Colitis. Inflamm Bowel Dis. 2024 Jun 03; 30(6):939-949.
    View in: PubMed
    Score: 0.045
  8. Utility of the Endoscopic Healing Index in Identifying Active Inflammation in Patients with Crohn's Disease: Real World Data from a Tertiary Center. Dig Dis Sci. 2024 Aug; 69(8):2955-2960.
    View in: PubMed
    Score: 0.045
  9. Ozanimod-exposed Patients with Ulcerative Colitis Undergoing Total Colectomy Exhibit Unique Lymph Node Histological Changes. J Crohns Colitis. 2024 Apr 23; 18(4):638-641.
    View in: PubMed
    Score: 0.044
  10. Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center. Dig Dis Sci. 2024 Feb; 69(2):579-587.
    View in: PubMed
    Score: 0.043
  11. Risankizumab Effectiveness and Safety in Crohn's Disease: Real-world Data From a Large Tertiary Center. Clin Gastroenterol Hepatol. 2024 Jun; 22(6):1336-1338.e2.
    View in: PubMed
    Score: 0.043
  12. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol. 2022 01; 7(1):17-27.
    View in: PubMed
    Score: 0.038
  13. Ulcerative Colitis Patients Have Reduced Rectal Compliance Compared With Non-Inflammatory Bowel Disease Controls. Gastroenterology. 2022 01; 162(1):331-333.e1.
    View in: PubMed
    Score: 0.037
  14. Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. United European Gastroenterol J. 2021 06; 9(5):552-560.
    View in: PubMed
    Score: 0.036
  15. Cumulative Histologic Inflammation Predicts Colorectal Neoplasia in Ulcerative Colitis: A Validation Study. Inflamm Bowel Dis. 2021 01 19; 27(2):203-206.
    View in: PubMed
    Score: 0.036
  16. Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. J Crohns Colitis. 2020 Oct 05; 14(10):1345-1353.
    View in: PubMed
    Score: 0.035
  17. Quantitative Variable Assessment of Patellar Instability: An MRI-Based Study. AJR Am J Roentgenol. 2020 11; 215(5):1163-1170.
    View in: PubMed
    Score: 0.035
  18. Poor Sleep Quality in Crohn's Disease Is Associated With Disease Activity and Risk for Hospitalization or Surgery. Inflamm Bowel Dis. 2020 07 17; 26(8):1251-1259.
    View in: PubMed
    Score: 0.034
  19. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther. 2020 03; 51(6):637-643.
    View in: PubMed
    Score: 0.033
  20. Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn's Disease than Endoscopic Healing. Clin Gastroenterol Hepatol. 2020 10; 18(11):2518-2525.e1.
    View in: PubMed
    Score: 0.033
  21. Long-Duration Oral Vancomycin to Treat Clostridioides difficile in Patients With Inflammatory Bowel Disease Is Associated With a Low Rate of Recurrence. Am J Gastroenterol. 2019 12; 114(12):1904-1908.
    View in: PubMed
    Score: 0.033
  22. Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study. J Crohns Colitis. 2019 Sep 19; 13(9):1158-1162.
    View in: PubMed
    Score: 0.032
  23. Abnormal Pouchogram Predicts Pouch Failure Even in Asymptomatic Patients. Dis Colon Rectum. 2019 04; 62(4):463-469.
    View in: PubMed
    Score: 0.031
  24. Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Dig Dis Sci. 2019 07; 64(7):1945-1951.
    View in: PubMed
    Score: 0.031
  25. Emerging Therapies for Inflammatory Bowel Disease. Adv Ther. 2018 11; 35(11):1746-1762.
    View in: PubMed
    Score: 0.030
  26. Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2018 07; 52(6):537-544.
    View in: PubMed
    Score: 0.030
  27. [Nephrotic syndrome and microhematuria in a patient with nutcracker syndrome: Report of a case and review of the literature]. Internist (Berl). 2018 06; 59(6):608-614.
    View in: PubMed
    Score: 0.030
  28. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2019 02; 17(3):486-493.
    View in: PubMed
    Score: 0.029
  29. Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. Clin Gastroenterol Hepatol. 2019 01; 17(1):205-206.
    View in: PubMed
    Score: 0.029
  30. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis. 2018 03 19; 24(4):849-860.
    View in: PubMed
    Score: 0.029
  31. Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 04; 63(4):1016-1024.
    View in: PubMed
    Score: 0.029
  32. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018 Mar; 47(6):753-762.
    View in: PubMed
    Score: 0.029
  33. Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. Gastrointest Endosc. 2018 May; 87(5):1304-1309.
    View in: PubMed
    Score: 0.029
  34. Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors. Curr Med Res Opin. 2017 11; 33(11):1945-1953.
    View in: PubMed
    Score: 0.028
  35. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 Jul 01; 11(7):785-791.
    View in: PubMed
    Score: 0.028
  36. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States. PLoS One. 2017; 12(4):e0175099.
    View in: PubMed
    Score: 0.027
  37. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis. J Manag Care Spec Pharm. 2017 Aug; 23(8):859-867.
    View in: PubMed
    Score: 0.027
  38. Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay. Curr Med Res Opin. 2017 May; 33(5):837-843.
    View in: PubMed
    Score: 0.027
  39. Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. Clin Gastroenterol Hepatol. 2017 Oct; 15(10):1557-1564.e1.
    View in: PubMed
    Score: 0.027
  40. The Crohn's and Colitis Foundation of America Survey of Inflammatory Bowel Disease Patient Health Care Access. Inflamm Bowel Dis. 2017 02; 23(2):224-232.
    View in: PubMed
    Score: 0.027
  41. Assessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn's disease in the United States: a claims data analysis. Curr Med Res Opin. 2017 03; 33(3):529-536.
    View in: PubMed
    Score: 0.027
  42. Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 01; 23(1):152-157.
    View in: PubMed
    Score: 0.027
  43. Many Inflammatory Bowel Disease Patients Are Not Immune to Measles or Pertussis. Dig Dis Sci. 2016 10; 61(10):2972-2976.
    View in: PubMed
    Score: 0.026
  44. Safety and Efficacy of Live Measles Vaccine Administered to a Crohn's Disease Patient Receiving Vedolizumab. Am J Gastroenterol. 2016 04; 111(4):577.
    View in: PubMed
    Score: 0.025
  45. Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial. J Crohns Colitis. 2016 Aug; 10(8):925-33.
    View in: PubMed
    Score: 0.025
  46. Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. Dig Dis Sci. 2015 Nov; 60(11):3408-17.
    View in: PubMed
    Score: 0.025
  47. U.S. Patients with Ulcerative Colitis Do Not Have a Decreased Risk of Diverticulosis. Inflamm Bowel Dis. 2015 Sep; 21(9):2154-7.
    View in: PubMed
    Score: 0.024
  48. Penetrating Disease, Narcotic Use, and Loop Ostomy Are Associated with Ostomy and IBD-related Complications After Ostomy Surgery in Crohn's Disease Patients. J Gastrointest Surg. 2015 Oct; 19(10):1852-61.
    View in: PubMed
    Score: 0.024
  49. Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease. J Crohns Colitis. 2015 Apr; 9(4):312-7.
    View in: PubMed
    Score: 0.023
  50. Patchy colitis and interstitial lung disease. Gastroenterology. 2015 Jan; 148(1):26-7.
    View in: PubMed
    Score: 0.023
  51. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther. 2014 May; 39(10):1143-55.
    View in: PubMed
    Score: 0.022
  52. Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. Inflamm Bowel Dis. 2013 Nov; 19(12):2577-83.
    View in: PubMed
    Score: 0.022
  53. Curbing our enthusiasm for fecal transplantation in ulcerative colitis. Am J Gastroenterol. 2013 Oct; 108(10):1631-3.
    View in: PubMed
    Score: 0.021
  54. Chronic pouchitis versus recurrent Crohn's disease: a diagnostic challenge. Dig Dis Sci. 2013 Oct; 58(10):2748-50.
    View in: PubMed
    Score: 0.021
  55. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1601-8.e1-4.
    View in: PubMed
    Score: 0.021
  56. Patient perceptions of fecal microbiota transplantation for ulcerative colitis. Inflamm Bowel Dis. 2013 Jun; 19(7):1506-13.
    View in: PubMed
    Score: 0.021
  57. What you see is not always what you get: raising the bar on clinical trial methodology in ulcerative colitis. Gastroenterology. 2013 Jul; 145(1):45-47.
    View in: PubMed
    Score: 0.021
  58. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6.
    View in: PubMed
    Score: 0.021
  59. Long-term treatment of patients with a history of ulcerative colitis who develop gastritis and pan-enteritis after colectomy. J Clin Gastroenterol. 2013 Jan; 47(1):52-7.
    View in: PubMed
    Score: 0.020
  60. Colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection in a child. Am J Gastroenterol. 2012 Dec; 107(12):1930-1.
    View in: PubMed
    Score: 0.020
  61. Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis. 2012 Dec; 18(12):2225-31.
    View in: PubMed
    Score: 0.019
  62. Assessment of variables associated with smoking cessation in Crohn's disease. Dig Dis Sci. 2012 Apr; 57(4):1026-32.
    View in: PubMed
    Score: 0.019
  63. Total abdominal colectomy for refractory ulcerative colitis. Surgical treatment in evolution. J Gastrointest Surg. 2011 Nov; 15(11):1909-16.
    View in: PubMed
    Score: 0.019
  64. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflamm Bowel Dis. 2012 May; 18(5):818-25.
    View in: PubMed
    Score: 0.019
  65. Fecal bacteriotherapy for ulcerative colitis: patients are ready, are we? Inflamm Bowel Dis. 2012 Apr; 18(4):676-84.
    View in: PubMed
    Score: 0.018
  66. Dynamic neural networks supporting memory retrieval. Neuroimage. 2011 Jul 15; 57(2):608-16.
    View in: PubMed
    Score: 0.018
  67. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6.
    View in: PubMed
    Score: 0.018
  68. We once were blind and now we see: is it time to treat ulcerative colitis to achieve mucosal healing? Clin Gastroenterol Hepatol. 2011 Jun; 9(6):456-7.
    View in: PubMed
    Score: 0.018
  69. Active Crohn's disease in the small bowel: evaluation by diffusion weighted imaging and quantitative dynamic contrast enhanced MR imaging. J Magn Reson Imaging. 2011 Mar; 33(3):615-24.
    View in: PubMed
    Score: 0.018
  70. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. Aliment Pharmacol Ther. 2011 Mar; 33(6):672-8.
    View in: PubMed
    Score: 0.018
  71. The peri-appendiceal red patch in ulcerative colitis: review of the University of Chicago experience. Dig Dis Sci. 2010 Dec; 55(12):3495-501.
    View in: PubMed
    Score: 0.017
  72. Do colorectal cancer patients understand that their family is at risk? Dig Dis Sci. 2009 Nov; 54(11):2473-83.
    View in: PubMed
    Score: 0.016
  73. The impact of ulcerative colitis on patients' lives compared to other chronic diseases: a patient survey. Dig Dis Sci. 2010 Apr; 55(4):1044-52.
    View in: PubMed
    Score: 0.016
  74. Genetic testing for inflammatory bowel disease: focus group analysis of patients and family members. Genet Test Mol Biomarkers. 2009 Aug; 13(4):495-503.
    View in: PubMed
    Score: 0.016
  75. Positron emission tomography (PET) used to image subclinical inflammation associated with ulcerative colitis (UC) in remission. Inflamm Bowel Dis. 2009 May; 15(5):750-5.
    View in: PubMed
    Score: 0.016
  76. Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey. Inflamm Bowel Dis. 2009 Apr; 15(4):581-8.
    View in: PubMed
    Score: 0.016
  77. A rare case of granulocytic sarcoma in the mandible of a 4-year-old child: a case report and review of the literature. J Oral Maxillofac Surg. 2009 Feb; 67(2):410-6.
    View in: PubMed
    Score: 0.015
  78. Identification of patients at increased risk for colorectal cancer in an open access endoscopy center. J Clin Gastroenterol. 2008 Oct; 42(9):1025-31.
    View in: PubMed
    Score: 0.015
  79. Association between colorectal cancer and urologic cancers. Arch Intern Med. 2008 May 12; 168(9):1003-9.
    View in: PubMed
    Score: 0.015
  80. Corynebacterium bovis line related septicemia: a case report and review of the literature. Scand J Infect Dis. 2008; 40(6-7):575-7.
    View in: PubMed
    Score: 0.014
  81. p53 mutations are associated with dysplasia and progression of dysplasia in patients with Crohn's disease. Dig Dis Sci. 2008 Feb; 53(2):474-80.
    View in: PubMed
    Score: 0.014
  82. What is the most effective way to communicate results after endoscopy? Gastrointest Endosc. 2007 Jul; 66(1):108-12.
    View in: PubMed
    Score: 0.014
  83. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007 Apr; 13(4):367-71.
    View in: PubMed
    Score: 0.014
  84. Colonic infiltration with chronic myelomonocytic leukemia. Nat Clin Pract Gastroenterol Hepatol. 2007 Apr; 4(4):229-33.
    View in: PubMed
    Score: 0.014
  85. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006 Nov; 4(11):1346-50.
    View in: PubMed
    Score: 0.013
  86. Comparison of routine and unprepped CT colonography augmented by low fiber diet and stool tagging: a pilot study. Abdom Imaging. 2007 Jan-Feb; 32(1):96-104.
    View in: PubMed
    Score: 0.013
  87. Do patients with inflammatory bowel disease want genetic testing? Inflamm Bowel Dis. 2006 Jun; 12(6):497-502.
    View in: PubMed
    Score: 0.013
  88. Superior mesenteric vein thrombosis after colectomy in a patient with Crohn's disease. Nat Clin Pract Gastroenterol Hepatol. 2005 Jun; 2(6):281-5; quiz 1 p following 285.
    View in: PubMed
    Score: 0.012
  89. Multiomic analysis reveals cellular, transcriptomic and epigenetic changes in intestinal pouches of ulcerative colitis patients. Nat Commun. 2025 Jan 21; 16(1):904.
    View in: PubMed
    Score: 0.012
  90. Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies. J Crohns Colitis. 2025 Jan 11; 19(1).
    View in: PubMed
    Score: 0.012
  91. Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis. BMJ Open Gastroenterol. 2025 Jan 08; 12(1).
    View in: PubMed
    Score: 0.012
  92. Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2025 Feb; 10(2):138-153.
    View in: PubMed
    Score: 0.012
  93. Noninvasive, microbiome-based diagnosis of inflammatory bowel disease. Nat Med. 2024 Dec; 30(12):3555-3567.
    View in: PubMed
    Score: 0.011
  94. Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. N Engl J Med. 2024 Sep 26; 391(12):1119-1129.
    View in: PubMed
    Score: 0.011
  95. Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme. J Crohns Colitis. 2024 May 31; 18(5):695-707.
    View in: PubMed
    Score: 0.011
  96. Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Crohn's Disease in US and Europe: Results from the Cross-Sectional CONFIDE Study. Dig Dis Sci. 2024 Jul; 69(7):2333-2344.
    View in: PubMed
    Score: 0.011
  97. Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD. J Crohns Colitis. 2024 Apr 23; 18(4):548-559.
    View in: PubMed
    Score: 0.011
  98. Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure. Clin Gastroenterol Hepatol. 2024 Oct; 22(10):2096-2106.
    View in: PubMed
    Score: 0.011
  99. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. Lancet Gastroenterol Hepatol. 2024 Feb; 9(2):133-146.
    View in: PubMed
    Score: 0.011
  100. Long-Term Safety Outcomes of Fecal Microbiota Transplantation: Real-World Data Over 8 Years From the Hong Kong FMT Registry. Clin Gastroenterol Hepatol. 2024 Mar; 22(3):611-620.e12.
    View in: PubMed
    Score: 0.011
  101. Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial. Aliment Pharmacol Ther. 2023 01; 57(2):205-214.
    View in: PubMed
    Score: 0.010
  102. Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease. Am J Gastroenterol. 2021 12 01; 116(12):2410-2418.
    View in: PubMed
    Score: 0.009
  103. Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. Inflamm Bowel Dis. 2021 10 18; 27(10):1620-1625.
    View in: PubMed
    Score: 0.009
  104. Vedolizumab and Anti-Tumour Necrosis Factor a Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. J Crohns Colitis. 2021 Oct 07; 15(10):1694-1706.
    View in: PubMed
    Score: 0.009
  105. How to Navigate National Societal Organizations for Leadership Development and Academic Promotion: A Guide for Trainees and Young Faculty. Gastroenterology. 2021 11; 161(5):1361-1365.
    View in: PubMed
    Score: 0.009
  106. Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2021 10; 6(10):826-849.
    View in: PubMed
    Score: 0.009
  107. Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. J Crohns Colitis. 2021 Jul 05; 15(7):1130-1141.
    View in: PubMed
    Score: 0.009
  108. Fecal Microbiota Transplantation for Recurrent C difficile Infection During the COVID-19 Pandemic: Experience and Recommendations. Mayo Clin Proc. 2021 06; 96(6):1418-1425.
    View in: PubMed
    Score: 0.009
  109. Cardiac Corrected QT Interval Changes Among Patients Treated for COVID-19 Infection During the Early Phase of the Pandemic. JAMA Netw Open. 2021 04 01; 4(4):e216842.
    View in: PubMed
    Score: 0.009
  110. Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission. Aliment Pharmacol Ther. 2020 12; 52(11-12):1676-1682.
    View in: PubMed
    Score: 0.009
  111. Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes. Clin Gastroenterol Hepatol. 2021 11; 19(11):2444-2446.e2.
    View in: PubMed
    Score: 0.009
  112. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020 10; 52(8):1353-1365.
    View in: PubMed
    Score: 0.009
  113. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. Gastroenterology. 2020 12; 159(6):2052-2064.
    View in: PubMed
    Score: 0.009
  114. Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000 Aug; 12(8):855-62.
    View in: PubMed
    Score: 0.009
  115. Management of Acute Severe Ulcerative Colitis in a Pregnant Woman With COVID-19 Infection: A Case Report and Review of the Literature. Inflamm Bowel Dis. 2020 06 18; 26(7):971-973.
    View in: PubMed
    Score: 0.009
  116. Practical advice for management of inflammatory bowel diseases patients during the COVID-19 pandemic: World Endoscopy Organization Statement. Dig Endosc. 2020 Jul; 32(5):658-662.
    View in: PubMed
    Score: 0.009
  117. Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020 06; 51(12):1365-1372.
    View in: PubMed
    Score: 0.008
  118. Impact of Physician Payments on Microvascular Breast Reconstruction: An All-Payer Claim Database Analysis. Plast Reconstr Surg. 2020 Feb; 145(2):333-339.
    View in: PubMed
    Score: 0.008
  119. Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. Inflamm Bowel Dis. 2020 01 06; 26(2):304-313.
    View in: PubMed
    Score: 0.008
  120. Capsule Retention in Crohn's Disease: A Meta-analysis. Inflamm Bowel Dis. 2020 01 01; 26(1):33-42.
    View in: PubMed
    Score: 0.008
  121. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation. Inflamm Bowel Dis. 2020 01 01; 26(1):1-10.
    View in: PubMed
    Score: 0.008
  122. Exposure to Anti-tumor Necrosis Factor Medications Increases the Incidence of Pouchitis After Restorative Proctocolectomy in Patients With Ulcerative Colitis. Dis Colon Rectum. 2019 11; 62(11):1344-1351.
    View in: PubMed
    Score: 0.008
  123. Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2019 Aug 14; 13(8):1012-1024.
    View in: PubMed
    Score: 0.008
  124. IBD-associated Colon Cancers Differ in DNA Methylation and Gene Expression Profiles Compared With Sporadic Colon Cancers. J Crohns Colitis. 2019 Jul 25; 13(7):884-893.
    View in: PubMed
    Score: 0.008
  125. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
    View in: PubMed
    Score: 0.008
  126. Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. Dig Dis Sci. 2019 12; 64(12):3596-3601.
    View in: PubMed
    Score: 0.008
  127. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending. J Manag Care Spec Pharm. 2019 Jul; 25(7):770-779.
    View in: PubMed
    Score: 0.008
  128. Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers. Hum Pathol. 2019 07; 89:44-50.
    View in: PubMed
    Score: 0.008
  129. Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. Gastrointest Endosc. 2019 08; 90(2):269-275.
    View in: PubMed
    Score: 0.008
  130. Patient-provider communications about pharmacogenomic results increase patient recall of medication changes. Pharmacogenomics J. 2019 12; 19(6):528-537.
    View in: PubMed
    Score: 0.008
  131. The Influence of Physician Payments on the Method of Breast Reconstruction: A National Claims Analysis. Plast Reconstr Surg. 2018 10; 142(4):434e-442e.
    View in: PubMed
    Score: 0.008
  132. A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. Aliment Pharmacol Ther. 2018 11; 48(9):933-940.
    View in: PubMed
    Score: 0.008
  133. Utility of video capsule endoscopy for longitudinal monitoring of Crohn's disease activity in the small bowel: a prospective study. Gastrointest Endosc. 2018 12; 88(6):947-955.e2.
    View in: PubMed
    Score: 0.007
  134. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis. 2018 05 18; 24(6):1291-1297.
    View in: PubMed
    Score: 0.007
  135. Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. J Crohns Colitis. 2018 Apr 27; 12(5):621-626.
    View in: PubMed
    Score: 0.007
  136. Prevention of colonic neoplasia with polyethylene glycol: A short term randomized placebo-controlled double-blinded trial. PLoS One. 2018; 13(4):e0193544.
    View in: PubMed
    Score: 0.007
  137. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis. Dig Dis Sci. 2018 May; 63(5):1294-1301.
    View in: PubMed
    Score: 0.007
  138. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):502-509.
    View in: PubMed
    Score: 0.007
  139. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis. 2018 Jan 24; 12(2):145-156.
    View in: PubMed
    Score: 0.007
  140. Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. PLoS One. 2017; 12(8):e0182900.
    View in: PubMed
    Score: 0.007
  141. miR-4728-3p Functions as a Tumor Suppressor in Ulcerative Colitis-associated Colorectal Neoplasia Through Regulation of Focal Adhesion Signaling. Inflamm Bowel Dis. 2017 08; 23(8):1328-1337.
    View in: PubMed
    Score: 0.007
  142. Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Subclinical Inflammation in the Proximal Colon. Clin Gastroenterol Hepatol. 2018 Jan; 16(1):68-74.
    View in: PubMed
    Score: 0.007
  143. Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. Am J Gastroenterol. 2017 Sep; 112(9):1423-1429.
    View in: PubMed
    Score: 0.007
  144. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
    View in: PubMed
    Score: 0.007
  145. miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis-Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD. Clin Cancer Res. 2017 Sep 01; 23(17):5281-5291.
    View in: PubMed
    Score: 0.007
  146. Tracking microbial colonization in fecal microbiota transplantation experiments via genome-resolved metagenomics. Microbiome. 2017 05 04; 5(1):50.
    View in: PubMed
    Score: 0.007
  147. The Drivers of Discretionary Utilization: Clinical History Versus Physician Supply. Acad Med. 2017 05; 92(5):703-708.
    View in: PubMed
    Score: 0.007
  148. Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program. Clin Pharmacol Ther. 2017 07; 102(1):106-114.
    View in: PubMed
    Score: 0.007
  149. Long-term Efficacy of Vedolizumab for Crohn's Disease. J Crohns Colitis. 2017 Apr 01; 11(4):412-424.
    View in: PubMed
    Score: 0.007
  150. Long-term Efficacy of Vedolizumab for Ulcerative Colitis. J Crohns Colitis. 2017 Apr 01; 11(4):400-411.
    View in: PubMed
    Score: 0.007
  151. Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient-Physician Visits. Inflamm Bowel Dis. 2017 04; 23(4):494-501.
    View in: PubMed
    Score: 0.007
  152. Early Transcriptomic Changes in the Ileal Pouch Provide Insight into the Molecular Pathogenesis of Pouchitis and Ulcerative Colitis. Inflamm Bowel Dis. 2017 03; 23(3):366-378.
    View in: PubMed
    Score: 0.007
  153. Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. Aliment Pharmacol Ther. 2017 01; 45(2):264-275.
    View in: PubMed
    Score: 0.007
  154. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol. 2017 02; 15(2):229-239.e5.
    View in: PubMed
    Score: 0.007
  155. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 08; 22(8):1870-80.
    View in: PubMed
    Score: 0.007
  156. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. Inflamm Bowel Dis. 2016 08; 22(8):1881-6.
    View in: PubMed
    Score: 0.007
  157. Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. J Crohns Colitis. 2016 Dec; 10(12):1385-1394.
    View in: PubMed
    Score: 0.006
  158. Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. Am J Clin Nutr. 2016 07; 104(1):113-20.
    View in: PubMed
    Score: 0.006
  159. Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease. Inflamm Bowel Dis. 2016 May; 22(5):1027-31.
    View in: PubMed
    Score: 0.006
  160. Insights into the pathogenesis of ulcerative colitis from a murine model of stasis-induced dysbiosis, colonic metaplasia, and genetic susceptibility. Am J Physiol Gastrointest Liver Physiol. 2016 06 01; 310(11):G973-88.
    View in: PubMed
    Score: 0.006
  161. Clostridium Difficile Infection in Ulcerative Colitis: Can Alteration of the Gut-associated Microbiome Contribute to Pouch Failure? Inflamm Bowel Dis. 2016 Apr; 22(4):902-11.
    View in: PubMed
    Score: 0.006
  162. Patients with Ulcerative Colitis Are More Concerned About Complications of Their Disease than Side Effects of Medications. Inflamm Bowel Dis. 2016 Apr; 22(4):940-7.
    View in: PubMed
    Score: 0.006
  163. Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflamm Bowel Dis. 2016 Mar; 22(3):631-7.
    View in: PubMed
    Score: 0.006
  164. Association between serrated epithelial changes and colorectal dysplasia in inflammatory bowel disease. Gastrointest Endosc. 2016 Jul; 84(1):87-95.e1.
    View in: PubMed
    Score: 0.006
  165. Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin. Gut. 2017 02; 66(2):285-292.
    View in: PubMed
    Score: 0.006
  166. Health Insurance Paid Costs and Drivers of Costs for Patients With Crohn's Disease in the United States. Am J Gastroenterol. 2016 Jan; 111(1):15-23.
    View in: PubMed
    Score: 0.006
  167. Deep enteroscopy with a conventional colonoscope: initial multicenter study by using a through-the-scope balloon catheter system. Gastrointest Endosc. 2015 Nov; 82(5):855-60.
    View in: PubMed
    Score: 0.006
  168. Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. Clin Gastroenterol Hepatol. 2015 Nov; 13(11):1919-25.
    View in: PubMed
    Score: 0.006
  169. Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology. 2015 Jul; 149(1):223-37.
    View in: PubMed
    Score: 0.006
  170. Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis. 2014 Oct; 20(10):1722-8.
    View in: PubMed
    Score: 0.006
  171. Clinical presentation and disease course of inflammatory bowel disease differs by race in a large tertiary care hospital. Dig Dis Sci. 2014 Sep; 59(9):2228-35.
    View in: PubMed
    Score: 0.006
  172. Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2014 Jan; 20(1):14-20.
    View in: PubMed
    Score: 0.005
  173. Assessment of the relationship between quality of sleep and disease activity in inflammatory bowel disease patients. Inflamm Bowel Dis. 2013 Oct; 19(11):2440-3.
    View in: PubMed
    Score: 0.005
  174. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis. 2013 May; 19(6):1112-22.
    View in: PubMed
    Score: 0.005
  175. Subdural hemorrhage in pediatric patients with enlargement of the subarachnoid spaces. J Neurosurg Pediatr. 2013 Apr; 11(4):438-44.
    View in: PubMed
    Score: 0.005
  176. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013 Feb; 19(2):363-9.
    View in: PubMed
    Score: 0.005
  177. Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013 Mar; 37(5):546-54.
    View in: PubMed
    Score: 0.005
  178. Screening for sleep disorders in pediatric primary care: are we there yet? Clin Pediatr (Phila). 2012 Dec; 51(12):1125-9.
    View in: PubMed
    Score: 0.005
  179. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013 Mar; 11(3):286-92; quiz e24.
    View in: PubMed
    Score: 0.005
  180. Low-dose smoking resumption in ex-smokers with refractory ulcerative colitis. J Crohns Colitis. 2012 Aug; 6(7):756-62.
    View in: PubMed
    Score: 0.005
  181. miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis. 2012 Jan; 18(1):94-100.
    View in: PubMed
    Score: 0.005
  182. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut. 2011 Jul; 60(7):937-43.
    View in: PubMed
    Score: 0.004
  183. When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflamm Bowel Dis. 2010 Oct; 16(10):1658-62.
    View in: PubMed
    Score: 0.004
  184. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7.
    View in: PubMed
    Score: 0.004
  185. Quantitative analysis of dynamic contrast enhanced MRI for assessment of bowel inflammation in Crohn's disease pilot study. Acad Radiol. 2009 Oct; 16(10):1223-30.
    View in: PubMed
    Score: 0.004
  186. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009 Feb 01; 29(3):247-57.
    View in: PubMed
    Score: 0.004
  187. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008 Dec; 103(12):3132-41.
    View in: PubMed
    Score: 0.004
  188. Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest. 2008 Oct; 88(10):1110-20.
    View in: PubMed
    Score: 0.004
  189. Agile patency system eliminates risk of capsule retention in patients with known intestinal strictures who undergo capsule endoscopy. Gastrointest Endosc. 2008 May; 67(6):902-9.
    View in: PubMed
    Score: 0.004
  190. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. Lancet. 2005 Jan 22-28; 365(9456):305-11.
    View in: PubMed
    Score: 0.003
  191. Fever and right upper quadrant pain in a pregnant woman at 30 weeks' gestation. Nat Clin Pract Gastroenterol Hepatol. 2004 Dec; 1(2):113-6; quiz 1 p following 116.
    View in: PubMed
    Score: 0.003
  192. The case: can doctors say "enough"? Camb Q Healthc Ethics. 2003; 12(2):215-23.
    View in: PubMed
    Score: 0.003
  193. Computer-aided diagnosis scheme for detection of polyps at CT colonography. Radiographics. 2002 Jul-Aug; 22(4):963-79.
    View in: PubMed
    Score: 0.002
  194. Computerized detection of colonic polyps at CT colonography on the basis of volumetric features: pilot study. Radiology. 2002 Feb; 222(2):327-36.
    View in: PubMed
    Score: 0.002
  195. The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. Surgery. 2002 Jan; 131(1):6-15.
    View in: PubMed
    Score: 0.002
  196. Treatment of anal fissures with topical nitroglycerin. Expert Opin Pharmacother. 2001 Jan; 2(1):41-5.
    View in: PubMed
    Score: 0.002
  197. The Montefiore community children's project: a controlled study of cognitive and emotional problems of homeless mothers and children. J Urban Health. 1999 Mar; 76(1):39-50.
    View in: PubMed
    Score: 0.002
  198. CT colonography with three-dimensional problem solving for detection of colonic polyps. AJR Am J Roentgenol. 1998 Oct; 171(4):989-95.
    View in: PubMed
    Score: 0.002
  199. Tumor angiogenesis in primary and metastatic colorectal cancers. Dis Colon Rectum. 1996 Oct; 39(10):1073-80.
    View in: PubMed
    Score: 0.002
  200. Gadolinium zeolite as an oral contrast agent for magnetic resonance imaging. J Magn Reson Imaging. 1995 Sep-Oct; 5(5):499-508.
    View in: PubMed
    Score: 0.002
  201. Regional expression of murine intestinal immune cells in normal and isografted intestine. Cell Immunol. 1995 Jul; 163(2):198-205.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.